The drug metabolizing capacity of patients with liver disease varies with the characteristics and the state of the disease. The aim of our studies on patients with various chronic liver diseases was to get information about the rational dosage for these patients. Our method in the first phase was antipyrine kinetics (hydroxylation), in the second phase sulfadimidine kinetics (acetylation) and menthol loading (glucuronidation). The induced state was investigated by D-glucaric acid excretion. Experimental trials: 1) comparison of groups of patients with moderate and severe liver diseases with each other, or with the normal control (two sample t test); 2) comparison of various groups of patients with each other and with the normal control (variance analysis); 3) research of potential correlation between the kinetic and biochemical parameters (correlation analysis); 4) reclassification studies with the use of kinetic and biochemical parameters (discrimination analysis). We discuss the practical advantage of the various experimental trials. The most important conclusion is that the reclassification by discrimination analysis gives important data to the economic planning of experiments.

Download full-text PDF

Source

Publication Analysis

Top Keywords

liver diseases
12
experimental trials
12
capacity patients
8
patients chronic
8
chronic liver
8
comparison groups
8
groups patients
8
normal control
8
kinetic biochemical
8
biochemical parameters
8

Similar Publications

Background & Aims: Hepatic encephalopathy (HE), one of the most serious prognostic factors for mortality in alcohol-related cirrhosis (ALD cirrhosis), is not recorded in Danish healthcare registries. However, treatment of HE with lactulose, the universal first-line treatment, can be identified through data on filled prescriptions. This study aimed to investigate if lactulose can be used as a surrogate marker of HE.

View Article and Find Full Text PDF

Introduction: Colorectal cancer (CRC) is the second most common cause of cancer-related deaths globally. The gut microbiota, along with adenomatous polyps (AP), has emerged as a plausible contributor to CRC progression. This study aimed to scrutinize the impact of the FadA antigen derived from Fusobacterium nucleatum on the expression levels of the ANXA2 ceRNA network and assess its relevance to CRC advancement.

View Article and Find Full Text PDF

This study aimed to identify shared gene expression related to circadian rhythm disruption in polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD) to discover common diagnostic biomarkers. Visceral fat RNA samples were collected from 12 PCOS and 14 non-PCOS patients, a sample size representing the clinical situation and sufficient to capture PCOS gene expression profiles. Along with liver transcriptome profiles from NAFLD patients, these data were analyzed to identify crosstalk circadian rhythm-related genes (CRRGs) between the diseases.

View Article and Find Full Text PDF

Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.

Clin Exp Med

January 2025

Department of Thoracic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Introduction Recently, immune cells within the tumor microenvironment (TME) have become crucial in regulating cancer progression and treatment responses. The dynamic interactions between tumors and immune cells are emerging as a promising strategy to activate the host's immune system against various cancers. The development and progression of hepatocellular carcinoma (HCC) involve complex biological processes, with the role of the TME and tumor phenotypes still not fully understood.

View Article and Find Full Text PDF

Purpose Of Review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, characterized by hepatic steatosis with at least one cardiometabolic risk factor. Patients with MASLD are at increased risk for the occurrence of cardiovascular events. Within this review article, we aimed to provide an update on the pathophysiology of MASLD, its interplay with cardiovascular disease, and current treatment strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!